Platelet-derived serotonin links vascular disease and tissue fibrosis.
Clara Dees, Alfiya Akhmetshina, Pawel Zerr, Nicole Reich, Katrin Palumbo, Angelika Horn, Astrid Jüngel, Christian Beyer, Gerhard Krönke, Jochen Zwerina, et al.

To cite this version:
Platelet-derived serotonin links vascular disease and tissue fibrosis

Clara Dees,1,2 Alihya Akhmetshina,1,2 Pawel Zerr,1,2 Nicole Reich,1,2 Katrin Palumbo,1,2 Angelika Horn,1,2 Astrid Jüngel,3,4 Christian Beyer,1,2 Gerhard Krönke,1,2 Jochen Zwerina,1,2 Rudolf Reiter,5 Natalia Alenina,6 Luc Maroteaux,7 Steffen Gay,3,4 Georg Schett,1,2 Oliver Distler,3,4 and Jörg H.W. Distler1,2

1Department of Internal Medicine 3 and 2Institute for Clinical Immunology, University of Erlangen-Nuremberg, 91054 Erlangen, Germany
2Center of Experimental Rheumatology and 3Zurich Center of Integrative Human Physiology, University Hospital Zurich, 8091 Zurich, Switzerland
4ErgolEx Pharma GmbH, CH-9050 Appenzell, Switzerland
5Max Delbrück Center for Molecular Medicine Berlin-Buch, 13092 Berlin, Germany
6Department of Transplantation Medicine, University of Lausanne, CH-1011 Lausanne, Switzerland
7Institut National de la Santé et de la Recherche Médicale Unité 839, Institut du Fer à Moulin, 75005 Paris, France

Abbreviations used: 5-HT, 5-hydroxytryptamine; mRNA, messenger RNA; MTT, microtiter tetrazolium; siRNA, small interfering RNA; SSc, systemic sclerosis.

Systemic fibrotic diseases such as systemic sclerosis (SSc) and organ-specific fibrosis such as kidney fibrosis, idiopathic pulmonary fibrosis, and liver cirrhosis share common pathophysiological mechanisms (Bataller and Brenner, 2005; Varga and Abraham, 2007; Strieter and Mehrad, 2009). Tissue fibrosis results from an increased release of extracellular matrix from aberrantly activated fibroblasts (Varga and Abraham, 2007; Gabrielli et al., 2009). The accumulating extracellular matrix disrupts the physiological tissue structure, leading to organ dysfunction and contributing to the high morbidity and increased mortality of affected patients (Chung et al., 2007; Steen and Medsger, 2007). However, the mechanisms for pathological fibroblast activation are incompletely understood. Consequently, therapeutic approaches selectively targeting the molecular activation of fibroblasts are not yet available for clinical use.

Tissue fibrosis is preceded by microvascular injury in SSc, leading to a progressive loss of capillaries (Gabrielli et al., 2009). The vascular damage with exposure of subendothelial connective tissue results in ongoing activation of platelets. The levels of several platelet-derived molecules such as β-thrombomodulin, platelet factor 4, and platelet-derived growth factor are elevated in SSc patients (Kahaleh et al., 1982; Postlethwaite and Chiang, 2007). In addition, elevated levels of circulating platelet aggregates
have also been described (Kahaleh et al., 1982). Moreover, platelets from SSC patients express markers of activation such as increased expression of the 65-kD receptor for type I collagen and enhanced activity of phosphatidylinositol-3 kinase (Postlethwaite and Chiang, 2007). However, the role of platelet activation in the pathogenesis of SSC and other fibrotic diseases has not yet been established.

5-Hydroxytryptamine (5-HT; serotonin) is another potent mediator, which is released upon activation of platelets and is elevated in the blood of SSC patients (Stachów et al., 1979; Biondi et al., 1988; Hervé et al., 1995). The rate-limiting step of 5-HT synthesis is catalyzed by TPHs (tryptophan hydroxylases), whereof two isoforms have been described: TPH1 is mainly expressed in the periphery, whereas the expression of TPH2 is restricted to neuronal cells and the central nervous system (Walther et al., 2003a).

Based on (a) the activation of platelets upon microvascular injury, (b) the release of 5-HT during platelet activation, and (c) the potent biological effects of 5-HT, we hypothesized that 5-HT signaling might be involved in the pathogenesis of fibrosis. The cellular effects of 5-HT are mediated by seven families of 5-HT receptors, 5-HT1 to 5-HT7, some of which comprise several different members (Humphrey et al., 1993). Nonselective antagonists of 5-HT2 signaling such as terguride and cyproheptadine are already in current therapeutic use. A low rate of side effects has been observed in long-term follow-ups, suggesting that inhibition of 5-HT2 receptor signaling is well tolerated in humans (von Werner et al., 1989; Moeret et al., 1991). In addition, selective inhibitors have been developed targeting individual members of the 5-HT2 subfamily, including SB 204741, which inhibits 5-HT2B in pharmacologically relevant concentrations (Bonhaus et al., 1995; Glusa and Pertz, 2000). Using pharmacologic as well as genetic approaches and different experimental models of fibrosis, we demonstrate that 5-HT/5-HT2B signaling plays a central role in skin fibrosis. Together with the clinical availability of selective small molecular weight inhibitors, targeting 5-HT2B signaling might be a promising strategy for the treatment of fibrosis.

RESULTS

5-HT stimulates the production of extracellular matrix in SSC and healthy dermal fibroblasts

We first analyzed whether 5-HT stimulates the production of extracellular matrix. Therefore, fibroblasts from SSC patients and healthy subjects were stimulated with 5-HT at biologically relevant concentrations (Kasho et al., 1998; Wouters et al., 2007). 5-HT dose-dependently induced the expression of extracellular matrix proteins with maximal induction at a concentration of 1 µM (Fig. 1, A–D). Higher concentrations of 5-HT did not further increase the expression of extracellular matrix proteins but resulted in toxic effects (unpublished data). 5-HT increased the expression of col 1a1 by 21 ± 14% (P < 0.05; Fig. 1 A). In addition to col 1a1, 5-HT also induced the expression of col 1a2 and fibronectin-1 in a dose-dependent manner (Fig. 1, B and C). Similarly, the release of collagen protein from SSC fibroblasts was increased by up to 198 ± 53% (P < 0.05; Fig. 1 D). 5-HT also induced the expression of collagen in dermal fibroblasts from healthy individuals without significant differences to fibroblasts from SSC patients (Fig. 1, A–D). 5-HT did not enhance the stability of type I collagen or fibronectin-1 messenger RNA (mRNA; Fig. S1, A–C) but stimulated the release of collagen by increasing transcription in reporter assays (P = 0.05; Fig. S1 D).

The profibrotic effects of 5-HT are mediated by 5-HT2B

Consistent with a previous study, we observed that three different receptors for 5-HT are expressed in dermal fibroblasts: 5-HT1B, 5-HT2A, and 5-HT2B (Slominski et al., 2003). In contrast to 5-HT1B and 5-HT2A, the mRNA levels of 5-HT2B were up-regulated by 143 ± 17% in SSC fibroblasts compared with healthy controls (P < 0.05; unpublished data). To investigate which of these receptors mediates the profibrotic effects of 5-HT, dermal fibroblasts were incubated with selective serotonin receptor inhibitors. Inhibition of 5-HT1B by SB 224289 did not reduce the stimulatory effects of 5-HT on extracellular matrix production in SSC fibroblasts (Fig. 2, A–D). In contrast, the 5-HT2 inhibitor terguride decreased mRNA levels of col 1a1, col 1a2, and fibronectin-1 and also the release of collagen protein in a dose-dependent manner (Fig. S2, A–D). Most pronounced effects were observed at a concentration of 1.0 µM, with an almost complete blockade of 5-HT–induced extracellular matrix expression. To discriminate between 5-HT2A and 5-HT2B, the 5-HT2A inhibitor ketanserin and the 5-HT2B antagonist SB

Figure 1. 5-HT stimulates the production of extracellular matrix in dermal fibroblasts. (A–C) mRNA levels of col 1a1 (A), col 1a2 (B), and fibronectin-1 (C) after stimulation of SSC and healthy dermal fibroblasts with 5-HT. (D) The release of collagen protein from dermal fibroblasts upon 5-HT stimulation (n = 5 each). *, P < 0.05 compared with controls. The experiment was performed in two independent series. Error bars indicate SE.
5-HT2B is overexpressed in skin of SSc patients

After demonstrating that 5-HT exerts its profibrotic effects via 5-HT2B, we were interested whether 5-HT2B might be up-regulated in human fibrotic diseases. 5-HT2B was detectable by immunohistochemistry in the fibrotic skin of SSc patients as well as in normal skin of healthy individuals (Fig. 3). However, expression of 5-HT2B was strongly increased in fibrotic tissue compared with unaffected tissue from healthy controls (Fig. 3 A). Double staining for the fibroblast-specific marker prolyl-4-hydroxylase β and 5-HT2B demonstrated that almost all fibroblasts stained positive for 5-HT2B in fibrotic tissue but not in controls (Fig. S2 E). Of note, intensive staining for 5-HT2B was observed in α-SMA (α smooth muscle actin)–positive, SM22-α (smooth muscle protein 22 α)–negative myofibroblasts in skin of SSc patients (Fig. 3 B). Together with a previous report of an increased serum concentration of 5-HT in SSc (Biondi et al., 1988), these findings suggest that the 5-HT/5-HT2B axis is up-regulated in systemic fibrotic disease.

5-HT2B activates TGF-β/Smad signaling

TGF-β has been identified as a key player in the pathogenesis of fibrosis (Varga and Abraham, 2007). When we compared the effects of 5-HT and TGF-β in col1a2 reporter assays, we observed different time kinetics. The stimulatory effects of 5-HT peaked after 24 h, whereas the maximal effects of TGF-β were observed after 6 h (Fig. S1 D). The delayed activation by 5-HT implicates that the profibrotic effects of 5-HT might be mediated indirectly by induction of a second messenger.

To investigate whether TGF-β itself might be this second mediator, we first analyzed the effects of 5-HT on the ex-
pression of TGF-β1 and of its target gene PAI-1 (plasminogen activator inhibitor 1). 5-HT dose-dependently increased mRNA levels of TGF-β1 and PAI-1 in SSc fibroblasts (Fig. 4, A and B). Furthermore, 5-HT induced a time-dependent increase in nuclear levels of phospho-Smad3, the typical intracellular mediator of TGF-β signaling (Fig. 4C). We next evaluated whether the profibrotic effects of 5-HT depend on TGF-β. Preincubation of SSc fibroblasts with neutralizing anti-

Figure 3. 5-HT2B is overexpressed in patients with SSc. (A) 5-HT2B was detectable by immunohistochemistry in fibroblasts, keratinocytes, and microvessels of SSc patients and controls. Two representative tissue sections and an isotype control are shown. (B) 5-HT2B expression in SM22-α-negative and α-SMA-positive myofibroblasts. A representative skin section of an SSc patient is shown. SM22-α as specific marker for vascular smooth muscle cells was stained with DAB, the myofibroblast marker α-SMA with Alexa Flour 594 (red), and 5-HT2B with Alexa Flour 488 (green; n = 8 each). The stainings were performed in three independent series. Bars: (A and B [top]) 50 µm; (B, bottom) 10 µm.

Figure 4. 5-HT exerts its profibrotic effects via activation of TGF-β/Smad-dependent pathways. (A and B) mRNA levels of TGF-β1 (A) and PAI-1 (B) in 5-HT-stimulated SSc fibroblasts (n = 9, three independent series). (C) Nuclear accumulation of p-Smad3 protein complexes after 12 and 24 h of stimulation with 1 µM 5-HT (n = 3). (D–F) mRNA expression of col 1a1 (D), col 1a2 (E), and fibronectin-1 (F) upon incubation with 500 ng/ml of neutralizing antibodies (Ab) against TGF-β1 in 5-HT-stimulated SSc fibroblasts (n = 5 each, two independent series). *, P < 0.05 compared with 5-HT-stimulated (D–F) or nonstimulated (A and B) controls. Error bars indicate SE.
bodies against TGF-β1 completely abrogated the profibrotic effects of 5-HT on mRNA expression of col1a1, col1a2, and fibronectin-1 (Fig. 4, D–F). The mRNA levels of col1a1, col1a2, and fibronectin-1 were only slightly reduced by neutralizing antibodies against TGF-β1 in unstimulated fibroblasts, suggesting that the observed effects of anti-TGF-β1 antibodies in 5-HT-stimulated fibroblasts were caused by blockade of the stimulatory effects of 5-HT rather than caused by effects on the basal synthesis (Fig. 4, D–F). Similar results were also obtained for healthy dermal fibroblasts (unpublished data).

Targeting of 5-HT2B exerts potent antifibrotic effects

We then assessed different inhibitors of 5-HT2 receptor for their antifibrotic activity in the mouse model of bleomycin-induced dermal fibrosis. Imatinib, a tyrosine kinase inhibitor with well established antifibrotic effects in this model, served as positive control (Wang et al., 2005; Distler et al., 2007a). No signs of toxicity were observed upon treatment with terguride, cyproheptadine, SB 204741, and imatinib. Injection of bleomycin potently stimulated the expression of 5-HT2B and induced dermal fibrosis (Fig. 5 A and Fig. S3 A). However, the 5-HT2 inhibitors terguride and cyproheptadine as well as the selective 5-HT2B inhibitor SB 204741 (Goldberg et al., 1979; Bonhaus et al., 1995; Glusa and Pertz, 2000; Jähniche et al., 2005) efficiently prevented bleomycin-induced dermal thickening (Fig. 5, A and B). Collagen content and myofibroblast counts were also dose-dependently reduced by the inhibition of 5-HT2B (Fig. 5, C and D).

The antifibrotic effects of the inhibition of 5-HT2 were further tested in a therapeutic approach in a modified bleomycin model. When the treatment with terguride was started after induction of fibrosis, terguride did not only prevent further progression, but induced regression of fibrosis (Fig. S3). Neutralizing antibodies against TGF-β1 completely abrogated the pro-fibrotic effects of 5-HT on mRNA expression of col1a1, col1a2, and fibronectin-1 (Fig. 4, D–F). The mRNA levels of col1a1, col1a2, and fibronectin-1 were only slightly reduced by neutralizing antibodies against TGF-β1 in unstimulated fibroblasts, suggesting that the observed effects of anti-TGF-β1 antibodies in 5-HT-stimulated fibroblasts were caused by blockade of the stimulatory effects of 5-HT rather than caused by effects on the basal synthesis (Fig. 4, D–F). Similar results were also obtained for healthy dermal fibroblasts (unpublished data).

Targeting of 5-HT2B exerts potent antifibrotic effects

We then assessed different inhibitors of 5-HT2 receptor for their antifibrotic activity in the mouse model of bleomycin-induced dermal fibrosis. Imatinib, a tyrosine kinase inhibitor with well established antifibrotic effects in this model, served as positive control (Wang et al., 2005; Distler et al., 2007a). No signs of toxicity were observed upon treatment with terguride, cyproheptadine, SB 204741, and imatinib. Injection of bleomycin potently stimulated the expression of 5-HT2B and induced dermal fibrosis (Fig. 5 A and Fig. S3 A). However, the 5-HT2 inhibitors terguride and cyproheptadine as well as the selective 5-HT2B inhibitor SB 204741 (Goldberg et al., 1979; Bonhaus et al., 1995; Glusa and Pertz, 2000; Jähniche et al., 2005) efficiently prevented bleomycin-induced dermal thickening (Fig. 5, A and B). Collagen content and myofibroblast counts were also dose-dependently reduced by the inhibition of 5-HT2B (Fig. 5, C and D).

The antifibrotic effects of the inhibition of 5-HT2 were further tested in a therapeutic approach in a modified bleomycin model. When the treatment with terguride was started after induction of fibrosis, terguride did not only prevent further progression, but induced regression of fibrosis (Fig. S3). Neutralizing antibodies against TGF-β1 completely abrogated the pro-fibrotic effects of 5-HT on mRNA expression of col1a1, col1a2, and fibronectin-1 (Fig. 4, D–F). The mRNA levels of col1a1, col1a2, and fibronectin-1 were only slightly reduced by neutralizing antibodies against TGF-β1 in unstimulated fibroblasts, suggesting that the observed effects of anti-TGF-β1 antibodies in 5-HT-stimulated fibroblasts were caused by blockade of the stimulatory effects of 5-HT rather than caused by effects on the basal synthesis (Fig. 4, D–F). Similar results were also obtained for healthy dermal fibroblasts (unpublished data).

Figure 5. Inhibition of 5-HT signaling by the 5-HT2 inhibitors terguride, cyproheptadine, and SB 204741 prevents accumulation of extracellular matrix in experimental dermal fibrosis. (A) Representative trichrome-stained tissue sections are shown: control mice injected intracutaneously with NaCl (n = 10), bleomycin-challenged mice without antifibrotic treatment (n = 10), mice receiving bleomycin and terguride at a concentration of 0.2 mg/kg/bid (n = 8), mice treated with bleomycin and terguride at a concentration of 0.6 mg/kg/bid (n = 8), mice treated with bleomycin and cyproheptadine at a concentration of 10 mg/kg/d (n = 6), mice treated with bleomycin and SB 204741 at a concentration of 5 mg/kg/d (n = 6), and mice treated with bleomycin and imatinib at a concentration of 5 mg/kg/d (n = 6). Bars, 100 μm. (B) Dermal thickening upon challenge with bleomycin and treatment with terguride, cyproheptadine, or imatinib. (C) Collagen accumulation in lesional skin as analyzed with the SirCol collagen assay. (D) Myofibroblast counts after treatment of bleomycin-challenged mice with terguride, cyproheptadine, SB 204741, or imatinib. *, P < 0.05 compared with bleomycin-treated mice without antifibrotic treatment. The experiment was performed in two independent series. Error bars indicate SE.
Dermal thickening decreased by 78 ± 4% in mice treated with terugride for the last 3 wk compared with mice challenged with bleomycin for 6 wk (P = 0.003) and by 66 ± 4% compared with mice injected with bleomycin for 3 wk (P = 0.002; Fig. 3C). The collagen content and the number of myofibroblasts were also efficiently reduced (Fig. S3, D and E).

To confirm the role of 5-HT2B in experimental fibrosis by a genetic approach, we evaluated the effects of bleomycin in mice lacking 5-HT2B. No histological changes or differences in dermal thickness were observed in untreated 5-HT2B+/− mice (Fig. 6 A). However, 5-HT2B−/− mice were almost completely protected from bleomycin-induced fibrosis. Bleomycin induced only minor dermal thickening, and the hydroxyproline content and the myofibroblast numbers did not increase in 5-HT2B−/− mice upon bleomycin challenge (Fig. 6, A–C).

Figure 6. Mice lacking 5-HT2B are protected from bleomycin-induced dermal fibrosis. (A) Trichrome-stained tissue sections of 5-HT2B−/− and wild-type mice. Representative tissue sections are shown: 5-HT2B+/+ mice injected with NaCl intracutaneously, 5-HT2B−/− mice receiving intracutaneous injections of NaCl, 5-HT2B+/+ mice receiving intracutaneous injections of bleomycin, and 5-HT2B−/− mice injected with bleomycin (n = 8 each). Bars, 100 µm. (B) Dermal thickening in bleomycin-challenged 5-HT2B−/− and wild-type mice. (C) Myofibroblast number in 5-HT2B−/− deficient and wild-type mice upon bleomycin challenge. *, P < 0.05 compared with bleomycin-injected wild-type mice. The experiment was performed in two independent series. Error bars indicate SE.

To assess the role of 5-HT2B in a less inflammation-dependent model of fibrosis, the Tsk-1 (tight skin 1) model was used. The Tsk-1 model is characterized by increased dermal thickness compared with matched wild-type mice because of a tandem duplication in the fibrillin-1 gene (Green et al., 1976). Consistent with the findings in human SSC and in bleomycin-induced fibrosis, 5-HT2B was overexpressed in skin sections of Tsk-1 mice (Fig. S4 A). Treatment with the 5-HT2B inhibitor SB 204741 normalized fibrotic changes observed in Tsk-1 mice (Fig. S4 B). Hypodermal thickening, collagen content, and the differentiation of resting fibroblasts into myofibroblasts in Tsk-1 mice were significantly reduced upon treatment with SB 204741 (Fig. S4, C–E).

Moreover, when 5-HT2B−/− mice were crossed with Tsk-1 mice, hypodermal thickening was significantly reduced in 5-HT2B−/−/Tsk-1 mice compared with 5-HT2B+/+ / Tsk-1 mice (Fig. 7, A and B). Furthermore, the collagen content and the myofibroblast numbers in the skin of 5-HT2B−/−/Tsk-1 mice were significantly decreased compared with 5-HT2B+/+ /Tsk-1 mice (Fig. 7, C and D).

Inhibition of platelet activation ameliorates bleomycin-induced skin fibrosis and the Tsk-1 phenotype

To confirm the link between increased platelet activation and increased 5-HT/5-HT2B signaling, we first measured the levels of 5-HT in fibrotic skin. The concentration of 5-HT in lesional skin increased to 5.8 ± 0.5 ng/mg in bleomycin-injected mice compared with 3.2 ± 0.2 ng/mg in control mice (P = 0.02). In the Tsk-1 model, the concentration of 5-HT was increased from 4.0 ± 0.4 ng/mg to 6.7 ± 1.0 ng/mg (P = 0.04). Thus, levels of 5-HT are up-regulated in different models of experimental fibrosis in accordance with the increased levels seen in human SSC (Stachów et al., 1979; Biondi et al., 1988).

Because the vast majority of 5-HT in nonneuronal tissues is derived from platelets, we hypothesized that inhibition of platelet activation might reduce the tissue levels of 5-HT and prevent experimental fibrosis. Indeed, treatment with the P2Y12 receptor inhibitor clopidogrel reduced the 5-HT content in the fibrotic skin of bleomycin-challenged mice by 58 ± 21% (P = 0.03). In parallel, clopidogrel decreased dermal thickening by 61 ± 13% compared with control mice (P = 0.001; Fig. S5, A and B). Consistently, the collagen content and the myofibroblast counts were significantly reduced (Fig. S5, C and D).

Hypodermal thickening in Tsk-1 mice was also reduced by 51 ± 16% (P = 0.009) upon treatment with clopidogrel (Fig. S5, E and F). Additionally, the collagen content and the number of activated myofibroblasts in skin were significantly decreased (Fig. S5, G and H).

Lack of 5-HT in platelets via knockout of TPH1 prevents experimental dermal fibrosis

Platelet granules do not only contain 5-HT but also other growth factors. To demonstrate that 5-HT is the major profibrotic mediator released by platelets, we investigated the outcome of TPH1-deficient (TPH1−/−) mice in experimental fibrosis. TPH1−/− mice do not completely lack 5-HT, but
total blood levels of 5-HT are reduced to 5% as compared with wild-type animals (Walther et al., 2003b). Consistent with an important role of platelet-derived 5-HT in fibrosis, the profibrotic effects of bleomycin were markedly reduced in TPH1−/− mice (Fig. 8 A). Dermal thickening was decreased by 61 ± 6% (P = 0.004), and the collagen content as well as myofibroblast counts were significantly reduced in TPH1−/− mice as compared with TPH1+/+ mice (Fig. 8, B–D).

**DISCUSSION**

Herein, we demonstrate that 5-HT2B signaling plays a central role for fibrosis. Several experimental levels such as 5-HT2B−null mice and treatment with small molecule inhibitors as well as in vitro and ex vivo studies in humans suggested that binding of 5-HT to its receptor 5-HT2B is a key step in tissue fibrosis. We believe that these findings have direct clinical implications: potent inhibitors of 5-HT2 receptors, including cyproheptadine and terguride used in our study as well as mianserin and lisuride, are already in clinical use and are well tolerated (Obeso et al., 1986; von Werner et al., 1989; Moertel et al., 1991; Szegedi and Schwertfeger, 2005). Furthermore, selective inhibitors of 5-HT2B are in clinical development and might be available in the near future. Thus, inhibition of 5-HT2B might be a promising novel therapeutic approach as efficient antifibrotic therapies are not yet available.

Patients affected with SSc develop a characteristic microangiopathy as the result of ongoing endothelial cell damage and endothelial cell activation early in the course of the disease, before tissue fibrosis becomes evident (Sgonc et al., 1996; Varga and Abraham, 2007). Loss of the anticoagulant properties of the endothelial cell layer results in platelet activation and the release of bioactive molecules such as β-thrombomodulin and vascular endothelial growth factor, which are increased in the serum of SSc patients (Soma et al., 1993; Mercié et al., 1995; Distler et al., 2002). Platelets are also the largest storage pool for 5-HT, and elevated plasma levels of 5-HT have been observed in systemic fibrosis (Biondi et al., 1988). Thus, microangiopathy with subsequent

---

**Figure 7.** Deficiency of 5-HT2B corrects the histological changes in Tsk-1 mice. (A) Representative sections of trichrome staining are shown: 5-HT2B+/+ mice without Tsk-1 allele (n = 5), 5-HT2B−/− mice without Tsk-1 allele (n = 8), 5-HT2B+/+Tsk-1 mice (n = 5), and 5-HT2B−/−Tsk-1 mice (n = 8). Vertical bars indicate the hypodermal thickness. Bars, 250 μm. (B) Hypodermal thickness in 5-HT2B−deficient Tsk-1 mice. (C) Collagen content in the skin of 5-HT2B−/−Tsk-1 mice. (D) Myofibroblast counts in Tsk-1 mice after knockdown of 5-HT2B. *P < 0.05 compared with 5-HT2B+/+Tsk-1 mice. The measurements were performed twice. Error bars indicate SE.
platelet activation and increased release of 5-HT might further activate 5-HT/5-HT2B signaling in addition to the 5-HT2B overexpression in fibrotic diseases. Indeed, inhibition of platelet activation or selective inhibition of the synthesis of 5-HT prevents experimental fibrosis in different mouse models, thereby highlighting the role of platelet activation in fibrosis.

Our study could also explain the molecular mechanism of the clinical association between carcinoid tumors and fibrosis. Carcinoid tumors are neuroendocrine tumors producing large amounts of 5-HT. Tissue fibrosis is often found in patients with carcinoid tumors, both locally and systemically (Modlin et al., 2004). Local tissue fibrosis in the peritumoral tissue is found in most patients. The accumulation of extracellular matrix might be substantial and by far exceed the actual tumor volume (Moertel et al., 1961; Makridis et al., 1996). The most common systemic fibrotic manifestation is carcinoid heart disease with fibrotic changes of the cardiac valves (Hallen, 1964). The lesions are located on the mural and valvular endocardium and consist of a matrix-rich stroma and interspersed myofibroblasts, which were also found in an animal model of carcinoid tumors (Gustafsson et al., 2005).

Figure 8. Mice lacking TPH1 are protected from bleomycin-induced dermal fibrosis. (A) Trichrome-stained tissue sections are shown: TPH1+/+ mice injected with NaCl intracutaneously (n = 7), TPH1−/− mice with intracutaneous injections of NaCl (n = 5), bleomycin-injected TPH1+/+ mice (n = 7), and TPH1−/− mice challenged with bleomycin (n = 5). Bars, 100 µm. (B) Dermal thickness in bleomycin-challenged TPH1-deficient mice. (C) Collagen protein content in bleomycin-challenged TPH1−/− mice as analyzed by hydroxyproline assay. (D) Changes in the number of α-SMA–positive myofibroblasts upon bleomycin challenge in TPH1-deficient mice. *, P < 0.05 compared with bleomycin-injected wild-type mice. The experiment was performed in two independent series. Error bars indicate SE.
rine, anorexins like fenfluramine, or drugs of abuse as for example MDMA (3,4-methylenedioxyamphetamine; also known as ecstasy; Rothman et al., 2000; Setola et al., 2003; Hofmann et al., 2006; Roth, 2007). As we demonstrate herein that activation of 5-HT2B potently stimulates the production of extracellular matrix proteins, it might be concluded that activation of 5-HT2B by the metabolite methylergonovine might be sufficient to promote the development of fibrosis. The importance of 5-HT signaling for fibrotic diseases is supported by recent studies with 5-HT receptor antagonists in experimental pulmonary or liver fibrosis (Rudde et al., 2006; Fabre et al., 2008). Thus, our findings might have widespread implications, namely that inhibition of the 5-HT2B pathway might be a promising strategy for fibrotic disorders.

MATERIALS AND METHODS

Patients, mice, and fibroblast cultures. Fibroblast cultures were obtained from skin biopsies of SSc patients and healthy volunteers as described previously (Akhmetshina et al., 2008). All patients fulfilled the criteria for SSc as suggested by LeRoy and Medsger (2001). Patient characteristics are summarized in Table S1. All patients and controls signed a consent form approved by the local institutional review boards. All human protocols were approved by the ethical board of the University of Erlangen-Nuremberg.

ELISA. 4-mg skin biopsies of the injected area were analyzed by competitive ELISA for 5-HT using a serotonin ELISA kit (GenWay).

Stimulation with 5-HT and 5-HT receptor inhibition. For stimulation experiments, a special FCS depleted of 5-HT was used (HyClone). For activation experiments, a selective ELISA for 5-HT using a serotonin ELISA kit (GenWay).

Collagen measurements. Total soluble collagen in cell culture supernatants was quantified using the SirCol collagen assay (Biocolor; Akhmetshina et al., 2008). To detect also highly cross-linked collagen, the collagen content in skin samples was analyzed by determination of the hydroxyproline content (Woessner, 1961).

Western blot. Nuclear and cytoplasmic extracts were prepared as previously described (Andrews and Fuller, 1991; Khelifi et al., 2005). Polyvinylidene fluoride membranes were incubated with polyclonal rabbit anti–5-HT2B (Genex) or monoclonal rabbit anti–phospho-Smad3 antibodies (Cell Signaling Technology). Equal loading of proteins was confirmed by visualization of the nuclear protein lamin A/C (Cell Signaling Technology) and the cytoplasmic protein β-actin (Sigma–Aldrich). Quantification was performed with ImageJ software (version 1.41; National Institutes of Health).

Immunohistochemistry for 5-HT2B, α-SMA, and SM22α. Skin sections from SSc patients and controls were stained with polyclonal rabbit anti–5-HT2B antibodies. A subset of 5-HT2B–stained sections was double stained with the fibroblast marker prolyl-4-hydroxylase β (Acris Antibodies). To analyze the expression of 5-HT2B in myofibroblasts, we performed triple staining for 5-HT2B, the myofibroblast marker α-SMA (clone 1A4; Sigma–Aldrich), and SM22α (Abcam) as specific marker for vascular smooth muscle cells to distinguish myofibroblasts from vessels. Antibodies labeled with horseradish peroxidase (Dako), alkaline phosphatase (Jackson ImmunoResearch Laboratories, Inc.), and Alexa Fluor 488 or Alexa Fluor 594 (both Invitrogen) were used as secondary antibodies. The expression of SM22α and 5-HT2B in single- and double–stained sections was visualized with DAB (diaminobenzidine) peroxidase substrate solution (Sigma–Aldrich), and the expression of prolyl-4-hydroxylation β with BCP/NBT (5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium; Vector Laboratories). Isotype antibodies in the same concentration were used for controls. Myofibroblasts in mouse sections were identified by staining for α-SMA as described previously (Distler et al., 2007a).

MTT assay. The metabolic activity of dermal fibroblasts incubated with inhibitors of 5-HT2B was measured using the MTTT (3, [4, 5-dimethylthiazol-2-y]l) 2, 5-diphenyl-tetrazolium bromide) method (Distler et al., 2005). In brief, SSc and healthy dermal fibroblasts were incubated with terugride or SB 204741 in concentrations of 0.1 and 1.0 µM in 96-well plates for 20 h.
After removing 100 µl of the medium, MTT was added at a final concentration of 1 mg/ml, and the cells were incubated at 37°C for 4 h. After dilution with 300 µl of 0.04 N HCl in isopropanol, the cells were analyzed using the ELISA reader (Spectra MAX 190 microplate spectrophotometer; Molecular Devices) at a test wavelength of 570 nm and a control wavelength of 630 nm. Untreated fibroblasts were used as negative controls, and all other results were normalized to untreated cells. Fibroblasts incubated with 50% DMSO served as positive controls.

Quantification of apoptotic and necrotic cells. Dermal fibroblasts were incubated with terguride or SB 204741 for 7 d. The number of apoptotic and necrotic cells was analyzed as described previously (Düstler et al., 2007a).

Bleomycin-induced dermal fibrosis. Skin fibrosis was induced in 6-wk-old, pathogen-free, female DBA/2 mice (Charles River) by local injections of bleomycin for 21 d. Seven groups received subcutaneous or intracutaneous injections of 100 µl bleomycin dissolved in 0.9% NaCl at a concentration of 0.5 mg/ml in defined areas of the upper back every other day to induce dermal fibrosis. Six groups of bleomycin-challenged mice were treated with the P2Y2 receptor inhibitor clopidogrel (25 mg/kg/d) by oral gavage, terguride (0.2 mg/kg/d) by intraperitoneal injection, or imatinib (50 mg/kg/d) by ip injections, which served as positive control. One group with subcutaneous injections of 100 µl of 0.9% NaCl served as control group. After 21 d, animals were sacrificed by cervical dislocation.

The mouse model of bleomycin-induced dermal fibrosis was also used to evaluate a potential protection from fibrosis in mice lacking TPH1 or 5-HT2B. Four groups of mice were analyzed. Two groups consisted of TPH1-deficient FVB mice (n = 5) or 129/PAS mice lacking 5-HT2B (n = 8), whereas the other two groups consisted of wild-type FVB (n = 7) and 129/PAS mice (n = 8). Dermal fibrosis was induced in one group each by repeated injections of bleomycin, whereas the other two groups received sham treatment with subcutaneous injections of NaCl and served as controls.

Treatment of established fibrosis. For the treatment of established fibrosis, a modified model of bleomycin-induced dermal fibrosis was used. Six groups of mice were analyzed. Two groups of mice were challenged with bleomycin for 3 wk and for 6 wk, respectively. The third group received bleomycin injections for 3 wk followed by NaCl injections for the next 3 wk to control for spontaneous regression of fibrosis. To assess the effects of terguride for treatment of established fibrosis, mice were challenged with bleomycin for 6 wk and treated in parallel with terguride (0.6 mg/kg/d) for the last 3 wk. Two groups of mice receiving intracutaneous injections of 100 µl of 0.9% NaCl for 3 wk and 6 wk, respectively, were used as controls.

Inhibition of platelet aggregation and 5-HT2B signaling in Tsk-1 mice. B6.Cg-FmmM+m/+ +/+ /P15d+/f (Tsk-1) mice and age-matched pa/pa (wild type) controls were purchased from the Jackson Laboratory (Charles River). Four groups of mice were analyzed. Three groups of Tsk-1 mice were treated with clopidogrel (25 mg/kg/d) by oral gavage, SB 204741 (5 mg/kg/d) subcutaneously, or imatinib (50 mg/kg/d) by ip injections, which served as positive control. The fourth group consisted of pa/pa (control) mice, which also received subcutaneous injections of DMSO subcutaneously. The treatment was started at an age of 3 wk, and mice were sacrificed after 6 wk of treatment.

In addition, Tsk-1 mice were crossed with 5-HT2B−/− or TPH1−/− mice to yield Tsk-1 mice deficient for 5-HT2B or TPH1. The F2 generation consisting of 5-HT2B−/−/Tsk-1 (TPH1−/−/Tsk-1), 5-HT2B+/−/Tsk-1 (TPH1+/−/Tsk-1), 5-HT2B−/−/pa (TPH1−/−/pa), and 5-HT2B+/−/pa (TPH1+/−/pa) mice were sacrificed at an age of 10 wk for further analysis.

Genotyping of the mice was performed by PCR. The following primers were used: 5′-HT2B−/− (forward, 5′-CTGGTTATTCCGATGTTCCCTT−3′; reverse, 5′-AACCATAACACCTGTAATCTTGATAGAAT−3′), 5′-HT2B−/− (forward, 5′-AGCAATTCGGCTGCTCTGAT−3′; and reverse, 5′-AGCCACGCTATGTCCTGAT−3′), mutated fibrillin-1/tsk-1 (forward, 5′-GTTGGCAACTATACCTGCAT−3′; and reverse, 5′-CTTTCCTGTTAACATAGGA−3′), and TPH1 (forward, 5′-GCTTGCAAGGTGGTTCTC−3′; reverse 1, 5′-GCTTGCGCTACCCGTGATATT−3′; and reverse 2, 5′-CAGCTCTGTGATGACCGTA−3′).

Histological analysis. Paraffin-embedded histological sections were stained with hematoxylin and eosin for the determination of dermal thickness as described previously (Düstler et al., 2007a). For direct visualization of collagen fibers, trichrome staining was performed using the Mason’s Trichrome Staining kit (Sigma-Aldrich).

Statistics. Data are expressed as mean ± SE. The Wilcoxon signed rank tests for related samples and the Mann-Whitney U test for nonrelated samples were used for statistical analyses. A p-value of <0.05 was considered statistically significant.

Online supplemental material. Fig. S1 shows that 5-HT activates collagen transcription. Fig. S2 demonstrates that the 5-HT2 inhibitor terguride reduces the profibrotic effects of 5-HT. Fig. S3 shows that 5-HT2B is overexpressed in bleomycin-induced skin fibrosis and that terguride induces regression of preestablished fibrosis. Fig. S4 shows increased expression of 5-HT2B in Tsk-1 mice and that selective inhibition of 5-HT2B ameliorates histological changes in the Tsk-1 mouse model. Fig. S5 demonstrates that inhibition of platelet activation reduces experimental dermal fibrosis. Fig. S6 shows reduced hypodermal thickness in TPH1-deficient Tsk-1 mice. Table S1 lists the patient characteristics at date of biopsy. Table S2 shows the Ki values of the chemical inhibitors used in this study. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20101629/DC1.

This study was supported by the Deutsche Forschungsgemeinschaft (Di 1537/2-1), grant A20 of the Interdisciplinary Center of Clinical Research in Erlangen, a Career Support Award of Medicine of the Ernst Jung Foundation, and a research grant from ErgoNex Pharma GmbH, Switzerland.

The authors have no conflicting financial interests.

Submitted: 9 August 2010
Accepted: 23 March 2011

REFERENCES


Serotonin in fibrotic disease | Dees et al.
Author: Read proofs carefully. This is your ONLY opportunity to make changes. NO further alterations will be allowed after this point.

Author Queries

[AQ1]: Per JEM style, your affiliations were renumbered. Please make sure that all affiliation information is still correct.

[AQ2]: Does fibrillin-1 refer to a proper gene name? If so, it should appear in italics.

[AQ3]: By tsk-1, do you mean Tsk-1?

[AQ4]: By “concentrations from 0.01 to 1.0 µM,” do you mean concentrations from 0.01 to 10 µM?
Figure S1. 5-HT stimulates the transcription of col1a2 but does not affect the half-life of col1a2 mRNA. (A–C) The mRNA half-life of col1a1 (A), col1a2 (B), and fibronectin-1 (C) upon stimulation with 5-HT (n = 3 each). (D) Transcription of col1a2 in reporter assays after stimulation with 5-HT and TGF-β1 (n = 5, two independent series). Error bars indicate SE.
Figure S2. The 5-HT receptor antagonist terguride reduces the expression of extracellular matrix proteins. (A–C) mRNA levels of col 1a1 (A), col 1a2 (B), and fibronectin-1 (C) in 5-HT–stimulated fibroblasts incubated with terguride at concentrations from 0.01 to 1.0 µM in SSc and healthy dermal fibroblasts (n = 5 each, two independent series). (D) Release of collagen protein from SSc and healthy dermal fibroblasts upon incubation with terguride (n = 5).* P < 0.05 compared with 5-HT–stimulated cells. Error bars indicate SE. (E) 5-HT2B is overexpressed in fibroblasts in fibrotic tissue. Double staining for the fibroblast marker prolyl-4-hydroxylase β and 5-HT2B. Skin sections of an SSc patient and a healthy volunteer and fibroblasts are shown. 5-HT2B was stained with DAB (brown), and prolyl-4-hydroxylase β was stained with BCIP/NBT (dark blue). The stainings were performed in three independent series. Bars: (top row and bottom right) 50 µm; (bottom left) 10 µm.
Figure S3. 5-HT2B is overexpressed in bleomycin–induced skin fibrosis, and terguride induces regression of preestablished fibrosis. (A) 5-HT2B is overexpressed in experimental dermal fibrosis. Representative sections and fibroblasts are shown (n = 5 in two independent series). (B–E) Inhibition of 5-HT2 induces regression of preestablished fibrosis in the model of established bleomycin-induced skin fibrosis. (B) Trichrome staining of lesional skin. Representative tissue sections are shown (n = 8 each). (C) Dermal thickness after treatment of preestablished fibrosis with terguride at a dose of 0.6 mg/kg/bid from week 3 to 6. (D) The collagen content in lesional skin upon treatment with terguride. (E) Myofibroblast counts after treatment with terguride for the last 3 wk. *, P < 0.05 compared with mice challenged with bleomycin for 3 wk. The experiment was performed in two independent series. Error bars indicate SE. Bars: (A, NaCl, bleomycin, and isotype control) 25 µm; (A, bleomycin fibroblasts) 10 µm; (B) 100 µm.
Figure S4. Increased expression of 5-HT2B in Tsk−1 mice, and selective inhibition of 5-HT2B ameliorates histological changes in the Tsk−1 mouse model. (A) 5-HT2B is overexpressed in Tsk−1 mice. Representative sections and fibroblasts are shown (n = 5 in two independent series).
(B–E) Pharmacologic inhibition of 5-HT2B by SB 204741 ameliorates the Tsk−1 phenotype. (B) Representative trichrome-stained sections of control mice, untreated Tsk−1 mice, and Tsk−1 mice treated with SB 204741 at a dose of 5 mg/kg/d are shown (n = 8 each). Vertical bars indicate the hypodermal thickness. (C–E) Hypodermal thickening (C), collagen content (D), and myofibroblast counts (E) in Tsk−1 mice treated with SB 204741. *, P < 0.05 compared with untreated Tsk−1 mice. The experiment was performed in two independent series. Error bars indicate SE. Bars: (A, control, Tsk−1, and isotype control) 25 µm; (A, Tsk−1 fibroblasts) 10 µm; (B) 250 µm.
Figure S5. Inhibition of platelet aggregation ameliorates experimental bleomycin-induced dermal fibrosis and the Tsk-1 phenotype. (A) Tri-color-stained tissue sections of DBA/2 mice: control mice injected with NaCl ($n = 10$), bleomycin-challenged mice without treatment ($n = 10$), and mice injected with bleomycin and treated with clopidogrel at a concentration of 25 mg/kg/d ($n = 6$). (B) Dermal thickening in experimental dermal fibrosis after treatment with clopidogrel. (C) Collagen protein content in lesional skin in bleomycin-induced skin fibrosis analyzed by hydroxyproline assay. (D) Changes in α-SMA-positive myofibroblast counts upon bleomycin challenge and treatment with clopidogrel. (E) Tissue sections of Tsk-1 mice: control mice without the Tsk-1 allele ($n = 8$), untreated Tsk-1 mice ($n = 8$), and Tsk-1 mice treated with clopidogrel at 25 mg/kg/d ($n = 6$). Vertical bars indicate the hypodermal thickness. (F) Hypodermal thickness after treatment with clopidogrel in the Tsk-1 mouse model. (G) Collagen content in Tsk-1 mice after treatment with clopidogrel. (H) Effects of clopidogrel on the number of α-SMA-positive myofibroblasts in Tsk-1 mice. *, $P < 0.05$ compared with Tsk-1 or bleomycin-injected mice without clopidogrel treatment. The experiments were performed in two independent series. Error bars indicate SE. Bars: (A) 100 µm; (E) 250 µm.
Figure S6. Deficiency for TPH1 ameliorates histological changes in Tsk-1 mice. (A) Representative tissue sections of wild-type mice without the Tsk-1 allele (TPH1+/+ pa), TPH1+/−/pa mice, TPH1+/+Tsk-1 mice, and TPH1+/−/Tsk-1 mice are shown. Vertical bars indicate hypodermal thickness. Bars, 250 µm. (B–D) Hypodermal thickening (B), collagen content as analyzed by hydroxyproline assay (C), and myofibroblast counts (D) in TPH1+/−/Tsk-1 mice (* n = 8 each). *, P < 0.05 compared with TPH1+/+Tsk-1 mice. The measurements were performed twice. Error bars indicate SE.

Table S1. Characteristics of SSc patients at date of biopsy for generation of dermal fibroblast cultures

<table>
<thead>
<tr>
<th>Gender (F/M)</th>
<th>Age (median and range) yr</th>
<th>Disease subset (limited/diffuse)</th>
<th>Disease duration (median and range) yr</th>
<th>Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/2</td>
<td>53 (38–74)</td>
<td>11/3</td>
<td>7 (1–20)</td>
<td>No DMARDs, corticosteroids, or NSAIDs</td>
</tr>
</tbody>
</table>

DMARD, disease-modifying antirheumatic drug; F, female; M, male; NSAID, nonsteroidal antiinflammatory drug. The disease subset was determined according to the criteria proposed by LeRoy and Medsger (2001). Disease duration was measured from the onset of the first non-Raynaud symptoms attributable to SSc.

Table S2. Ki values of the chemical inhibitors according to the National Institute of Mental Health Ki Database

<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>5-HT1B</th>
<th>5-HT2A</th>
<th>5-HT2B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyproheptadine</td>
<td>ND</td>
<td>1.67</td>
<td>1.54</td>
</tr>
<tr>
<td>Ketanserin</td>
<td>4,350</td>
<td>2.25</td>
<td>911</td>
</tr>
<tr>
<td>SB 204741</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>94.92</td>
</tr>
<tr>
<td>SB 224289</td>
<td>6.91</td>
<td>5.012</td>
<td>1,349</td>
</tr>
<tr>
<td>Terguride</td>
<td>257</td>
<td>4.79</td>
<td>7.08</td>
</tr>
</tbody>
</table>
REFERENCE
Authorization of Publication Charges - *The Journal of Experimental Medicine*

<table>
<thead>
<tr>
<th>MS#</th>
<th>First Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>Month</td>
<td></td>
</tr>
</tbody>
</table>

Your signature is **required**.

**Article charges, offprints, authors’ alterations, and supplemental material** authorized by:

×

**signature of department head or fiscal officer**

**Publication Charges**

- **Article charge**: $0.07 per character, excluding spaces, Materials and methods, References, and Tables.
- **Supplemental Material**: $350.00 flat fee for all material.
- **Alterations**: Avoid changes in proof. The cost of authors’ alterations is $4.00 per change and will be added to your invoice. Figure reprocessing at the author’s request will be charged at $55.00 per subject.

**Terms**: Cash...No Discount.

Make out the institutional purchase order to The Rockefeller University Press to cover all your charges: article, offprint, supplemental material, and alteration – add “plus authors’ alteration charges” to your purchase order. **Manuscript number, author name, and journal name must be on purchase order. Please do not prepay your charges**; an exact invoice will be sent to you by The Rockefeller University Press after your article has been published. Purchase orders with incorrect totals may not be processed and invoices may be sent directly to the corresponding author. Checks must be drawn in U.S. currency on an American bank. All checks must have micro-encoding on the bottom of the check. Make checks and purchase orders payable to:


**Billing Instructions** *(please print or type)*

<table>
<thead>
<tr>
<th>Article charges, offprints, alterations, and supplemental material are to be charged to:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

OR

<table>
<thead>
<tr>
<th>Purchase Order No.:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Card Number</th>
<th>Expiration Date</th>
<th>Cardholder</th>
<th>Telephone Number</th>
<th>Fax Number</th>
</tr>
</thead>
</table>

×

**Signature required**

MasterCard, VISA, American Express, and Discover accepted. You will be notified before your card is charged.

*For split payment, please include a detailed cover letter.*

**Check one:**

- [ ] ORDERING OFFPRINTS — SEE PAGE 2
- [ ] NO OFFPRINTS ARE BEING ORDERED
Offprint & Poster Order Form • The Journal of Experimental Medicine

MS# ___________________ First Author ________________________________

Month ______________________

Offprints in multiples of 100 copies from the Journal of Experimental Medicine must be ordered at the time the author returns the page proof. The minimum quantity for which orders will be accepted is 100 copies. Shipment will be made by the printer approximately 21 days after publication. Please note, we cannot deliver to P.O. Boxes. Foreign postage will be assessed based on the weight and destination of the shipment.

Prices

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>100 offprints</td>
<td>$390</td>
<td>$490</td>
<td>$640</td>
<td>$765</td>
<td>$895</td>
<td>$1040</td>
<td>$1140</td>
<td>$235</td>
<td>$315</td>
</tr>
<tr>
<td>200 offprints</td>
<td>580</td>
<td>730</td>
<td>1015</td>
<td>1255</td>
<td>1525</td>
<td>1750</td>
<td>1995</td>
<td>395</td>
<td>440</td>
</tr>
<tr>
<td>Add’l 100s over 200</td>
<td>180</td>
<td>230</td>
<td>375</td>
<td>500</td>
<td>625</td>
<td>720</td>
<td>840</td>
<td>110</td>
<td>110</td>
</tr>
<tr>
<td>Poster of Cover (18” x 24”)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$100 (includes shipping, poster will be mailed rolled)</td>
<td></td>
</tr>
</tbody>
</table>

*Please note: Typeset covers are plain paper, stapled to the offprint, that have the article title and authors’ names on them.

**For posters of previous issue covers, please see our Poster Order Form, available at www.rupress.org/site/store/poster.pdf

Order

Offprints without covers __________
Offprints with covers __________  □ Typeset  □ Journal
Posters __________
TOTAL __________

Do not delay ordering your offprints. Orders must be in hand before the Journal goes to press. Please be sure the total order includes offprints for all co-authors who may want them. Orders received after the issue closes will incur a $40.00 late fee. Complete and return by fax with your corrected page proof within 48 hours to:

Fax: 212.327.8513

Shipping Instructions

Ship _____ offprints with/without covers _____ Posters  Ship _____ offprints with/without covers _____ Posters
Name ________________________________  Name ________________________________
Univ./Inst. ____________________________  Univ./Inst. ____________________________
Street ________________________________  Street ________________________________
__________________________________________________  ________________________________
City, State, Zip Code ____________________  City, State, Zip Code ____________________
__________________________________________________  ________________________________
Telephone ______________________________  Telephone ______________________________

PAGE 1 OF THIS FORM MUST BE COMPLETED
THE JOURNAL OF EXPERIMENTAL MEDICINE

FIGURE APPROVAL

Author: et al. MS#:

Embedded in your Rough Galley PDF are high resolution versions of your figure files. This is the only form of proof that you will see for the figures that will appear in your upcoming JEM article. The images in the PDF appear as they will in the final online version of your article. Note that colors must be converted to CMYK for the print version, and color shifts may occur. Our main concern is to retain your original RGB data, which can only be achieved in the online version. You will not receive a CMYK proof.

The embedded figures are your original files. The only changes you might notice should be dimensions, labeling, or arrangement of panels. Any color and grayscale should look exactly like or extremely close to your submitted files, though they have been compressed slightly to prevent unwieldy file size. If any figures need correction (if the message of your illustration is not conveyed on the figure proof, or if there is a labeling error), you must contact the Press office immediately.

RUP has placed your figures from the electronic files that you supplied, and we cannot be responsible for figure reproduction quality. Files must be prepared to journal specification if results are to meet your expectations. If reprocessing is required, you must supply the production office with a new high-quality file. **Reprocessing may delay publication. Authors will be charged for reprocessing unless there has been an error introduced by RUP.**

If you have any questions, please contact your Production Editor at 212-327-8527

PLEASE SIGN EITHER A OR B

<table>
<thead>
<tr>
<th>A. I approve all figures in my article.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Signature</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B (part I). I do not approve figure number(s)………………………………. I have described in an attached letter precisely what is not conveyed, and I have provided a corrected file. I am aware reprocessing may cause a delay in publication.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Signature</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B (part II). Does the author want to see revised figures (please circle one)? Yes No</th>
</tr>
</thead>
<tbody>
<tr>
<td>If “yes,” please supply the name and email address of an alternate at your institution who you’ve authorized to review your figures and give final approval/disapproval on your behalf. <strong>If you are not available when your revised files are ready and if an alternate contact has not been provided, your article will be delayed.</strong></td>
</tr>
<tr>
<td>Alternate’s Name</td>
</tr>
</tbody>
</table>

Please **SIGN and FAX** this form WITH YOUR CORRECTED PROOFS to:

THE JOURNAL OF EXPERIMENTAL MEDICINE Fax: 212-327-8513